Fig. 5

SIRT6 is involved in mediating the protective effects of FGF21 for mitochondria and ECs in vitro. A–C Western blots and qPCR for SIRT6 among different groups in vitro. n = 6 per group. D, F Representative images of immunofluorescence stain and statistics analysis for CD31 and SIRT6 among different groups 72 h after ICH in vivo. Red: CD31, Green: SIRT6, Blue: DAPI. n = 6 per group. E, G Representative images of Mitotracker stain and statistics analysis for si-NC treated group and siSIRT6 treated group. n = 6 per group. H, I Representative images of MitoSOX stain and statistics analysis for si-NC treated group and siSIRT6 treated group. n = 6 per group. J, K MnSOD and ATP test for si-NC treated and siSIRT6 treated group. n = 6 per group. L, M Cell viability and relative permeability test for si-NC treated group and siSIRT6 treated group. n = 6 per group. Scale bar: 20um (D) and Scale bar: 10 um (E, H). ^**P < 0.01, ^***P < 0.001 vs Control group and ^&&P < 0.01 vs OxyHb + Vehicle group by one-way ANOVA (A, C), ^***P < 0.001 vs Sham group and ^&P < 0.05 vs ICH + Vehicle group by one-way ANOVA (F), ^**P < 0.01, ^***P < 0.001 indicates OxyHb + Vehicle vs OxyHb + FGF21 group by two-way ANOVA (G, I), ^**P < 0.01, ^***P < 0.001 vs Control group, ^&P < 0.05, ^&&P < 0.01 vs OxyHb + Vehicle group and ^#P < 0.05, ^##P < 0.01 vs OxyHb + FGF21 + si-NC group by one-way ANOVA (J–M), ns: no significant. Values are presented as mean \(\pm\) SD